Executive Order Prompts Fast-Track Review After PSX-001 Cuts Anxiety Scores
PSX-001, an oral synthetic psilocybin for generalized anxiety disorder, cut HAM-A scores by 12.8 points vs. 3.6 for placebo, with 44% achieving ≥50% anxiety reduction and 27% remission in a 73-patient Phase 2 trial. An executive order directs FDA to fast-track psychedelic reviews and rescheduling, lowering regulatory barriers to psilocybin therapies.
1. Executive Order Details
The White House executive order mandates FDA to fast-track psychedelic compound reviews, establish Right to Try pathways for investigational psychedelics, and initiate DEA rescheduling upon successful Phase 3 trials, aiming to reduce longstanding regulatory hurdles for psilocybin therapies.
2. PSX-001 Phase 2 Data
In its 73-patient Phase 2 trial for generalized anxiety disorder, PSX-001 achieved a 12.8-point reduction in HAM-A scores versus 3.6 for placebo, with 44% of patients attaining ≥50% anxiety reduction and 27% reaching remission, showing no serious adverse events.
3. Financial Position and Development Plans
Incannex holds over $70 million in cash with no debt, maintains an active U.S. IND and plans to advance PSX-001 into Phase 3, leveraging the improved regulatory environment to expedite development and potential commercialization.